LILRB4/CD85k/ILT3 Protein, Human (HEK293, His-Avi)
Based on 1 Customer Validation
The LILRB4/CD85k/ILT3 protein is a key inhibitory receptor that plays a key role in immune regulation and tolerance. As a receptor for FN1, apolipoprotein APOE, and ALCAM/CD166, it inhibits receptor-mediated phosphorylation, intracellular calcium mobilization, and FCGR1A/CD64-mediated monocyte activation, thereby reducing TNF production. LILRB4/CD85k/ILT3 Protein, Human (HEK293, His-Avi) is the recombinant human-derived LILRB4/CD85k/ILT3 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
- Species: Human
- Source: HEK293
-
Storage:Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Biological Activity
Description
The LILRB4/CD85k/ILT3 protein is a key inhibitory receptor that plays a key role in immune regulation and tolerance. As a receptor for FN1, apolipoprotein APOE, and ALCAM/CD166, it inhibits receptor-mediated phosphorylation, intracellular calcium mobilization, and FCGR1A/CD64-mediated monocyte activation, thereby reducing TNF production. LILRB4/CD85k/ILT3 Protein, Human (HEK293, His-Avi) is the recombinant human-derived LILRB4/CD85k/ILT3 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
Background
LILRB4/CD85k/ILT3, an inhibitory receptor, plays a pivotal role in immune regulation and the establishment of immune tolerance. Functioning as a receptor for FN1, apolipoprotein APOE, and ALCAM/CD166, this protein is involved in diverse cellular processes. It inhibits receptor-mediated phosphorylation of cellular proteins and the mobilization of intracellular calcium ions, and it further down-regulates FCGR1A/CD64-mediated monocyte activation, leading to reduced TNF production. Additionally, LILRB4/ILT3 impedes T cell proliferation, inducing anergy, suppressing the differentiation of IFNG-producing CD8+ cytotoxic T cells, and promoting the generation of CD8+ T suppressor cells. It induces the up-regulation of CD86 on dendritic cells and interferes with TNFRSF5-signaling and NF-kappa-B up-regulation. The inhibitory effects are at least partially mediated through interactions with FN1 and the phosphatase PTPN6.
Verified Bioactivity
Immobilized Human LILRB4, His Tag at 1 μg/mL (100 μL/Well) on the plate. Dose response curve for Anti-LILRB4 Antibody, hFc Tag with the EC50 of 1.0-10.0 ng/mL determined by ELISA.
Technical Parameters
-
Species Human
-
Source HEK293
-
Tag C-Avi;C-6*His
-
Accession
Q8NHJ6-1 (Q22-H257)
-
Molecular Construction
-
N-term
-
LILRB4 (Q22-H257)
Accession # Q8NHJ6-1 -
6*His-Avi
-
C-term
-
-
Protein Length
Extracellular Domain
-
Synonyms
LILRB4; CD85 Antigen-Like Family Member K; Leukocyte Immunoglobulin Like Receptor B4; Monocyte Inhibitory Receptor HM18; LIR-5; Immunoglobulin-Like Transcript 3; ILT3; Leucocyte Ig-Like Receptor B4; LIR5; ILT-3; CD85k; HM18; Leukocyte Immunoglobulin-Like
-
AA Sequence
QAGPLPKPTLWAEPGSVISWGNSVTIWCQGTLEAREYRLDKEESPAPWDRQNPLEPKNKARFSIPSMTEDYAGRYRCYYRSPVGWSQPSDPLELVMTGAYSKPTLSALPSPLVTSGKSVTLLCQSRSPMDTFLLIKERAAHPLLHLRSEHGAQQHQAEFPMSPVTSVHGGTYRCFSSHGFSHYLLSHPSDPLELIVSGSLEDPRPSPTRSVSTAAGPEDQPLMPTGSVPHSGLRRH
-
Predicted Molecular Mass
28.6 kDa
-
Molecular Weight
Approximately 38-42 kDa, based on SDS-PAGE under reducing conditions, due to the glycosylation.
-
Purity
≥ 95%, as determined by Bis-Tris PAGE.
Product Properties
Lyophilized powder.
Lyophilized from a 0.22 μm filtered solution of PBS, pH 7.4, 8% trehalose.
<1 EU/μg, determined by LAL method.
It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH2O.
Stored at -20°C for 2 years from date of receipt. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.
Room temperature in continental US; may vary elsewhere.
Documentation
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)